The Insight Partners published latest research report on “CIN & HR-HPV Treatment Market Size Report, Share, Trends, Growth & Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type, Strain Type, Offering, Product Type, and End User”, the global market size is projected to reach USD 17,164.61 million by 2028 from USD 11,635.17 million in 2022.
The Insight Partners published latest research report on “CIN & HR-HPV Treatment Market Size Report, Share, Trends, Growth & Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type, Strain Type, Offering, Product Type, and End User”, the global market size is projected to reach USD 17,164.61 million by 2028 from USD 11,635.17 million in 2022. The market is estimated to grow with a CAGR of 6.7% from 2023 to 2028.
Request Sample PDF Brochure: https://www.theinsightpartners.com/sample/TIPRE00029878
CIN and HR-HPV Treatment Market: Competitive Landscape and Key Developments:
Fujirebio Europe NV, Qiagen NV, Zilico Ltd, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd, INOVIO Pharmaceuticals Inc, Bioneer Corp, Antiva Biosciences Inc, and Thermo Fisher Scientific Inc are a few of the key companies operating in the CIN and HR-HPV treatment market. These companies adopt product innovation strategies to meet evolving customer demands, which allows them to maintain their brand name. A few of the recent developments in the global CIN and HR-HPV treatment market are mentioned below:
• In June 2022, Roche launched a self-sampling solution for HPV diagnosis in countries accepting the CE mark. The new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically validated vaginal sample is analyzed with the Roche cobas HPV test on a Roche molecular instrument.
• In December 2021, INOVIO provided updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year follow-up of efficacy and safety data in participants from REVEAL1, completing enrollment in REVEAL2, and advancing its pre-treatment biomarker candidate for VGX-3100 to be further developed with QIAGEN.
• In October 2022, Fujirebio Europe and Self-screen BV formed a commercial collaboration to distribute the PreCursor-M+ methylation-specific molecular in-vitro diagnosis (IVD) assay (a trademark of Self-screen BV). The test is intended for qualitatively detecting the elevated methylation levels of cervical cancer biomarkers. It may be used as a triage follow-up test on women with HPV-positive results and ASCUS/LSIL cytology. The PreCursor-M+ assay completes Fujirebio’s HPV-specific molecular test portfolio.
Directly Purchase Premium Copy of CIN & HR-HPV Treatment Market Growth Report (2023-2028) at: https://www.theinsightpartners.com/buy/TIPRE00029878
High-risk human papillomavirus (HR-HPV) is associated with cervical intraepithelial neoplasia (CIN). Persistent infection with hrHPV results in invasive cervical cancer. HR-HPV subtypes, particularly HPV 16 and HPV 18, are known to cause cervical cancer. The Cervical Screening Program (CSP) is a notable initiative by the National Health Service (NHS) to reduce cervical cancer incidence and related mortality among people aged 24–64 through a systematic, quality-assured population-based screening program.
Global CIN & HR-HPV Treatment Market Share Report, Segmentations, Regional & Country Scope:
| Report Coverage | Details |
| Market Size Value in | USD 11,635.17 million in 2022 |
| Market Size Value by | USD 17,164.61 million by 2028 |
| Growth rate | CAGR of 6.7% from 2023 to 2028 |
| Forecast Period | 2023-2028 |
| Base Year | 2022 |
| No. of Pages | 245 |
| No. of Tables | 195 |
| No. of Charts & Figures | 85 |
| Historical data available | Yes |
| Segments covered | Disease Type, Strain Type, Offering, Product Type, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Companies Covered | Fujirebio Europe NV, Qiagen NV, Zilico Ltd , Abbott Laboratories , Cepheid, F. Hoffmann-La Roche Ltd , INOVIO Pharmaceuticals Inc, Bioneer Corp , Antiva Biosciences Inc , Thermo Fisher Scientific Inc. |
Browse key market insights spread across 245 pages with 195 list of tables & 85 list of figures from the report, “CIN & HR-HPV Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)” in detail along with the table of contents: https://www.theinsightpartners.com/reports/cin-and-hrhpv-treatment-market
Increase in Prevalence of Human Papillomavirus Infections to Drive Global CIN and HR-HPV Treatment Market Growth:
Cervical intraepithelial neoplasia (CIN), also called cervical dysplasia, is characterized by the formation of proliferative lesions with abnormal cell growth on the surface of the cervix. These lesions replace a part of or the entire cervical squamous epithelium, and they are perceived as precursors of cervical cancer. Cervical dysplasia is caused by HPV infection. Over 200 variants of HPV are known to cause infections among humans, and ~40 of these variants affect genitals upon spreading through sexual contact. 12 of these HPV types are associated with a high risk of cancer, and ~10 are associated with low-risk cancer. ~70% of cervical cancer cases are caused by HPV type 16 and type 18, which are HR-HPV serotypes. According to the American Cancer Society, 9 out of 10 cervical cancers are caused by HPV; in 2023, ~13,960 women in the US are likely to be diagnosed with cervical cancer, and the disease is expected to cause death among ~4,310 women. According to a study published in the National Library of Medicine, in 2022, most cervical cancer cases were caused by HPV 16, accounting for 55–60% of cervical cancer cases reported worldwide in that year. HPV 18 accounts for 10–15% of cervical cancer cases in the world. A persistent HPV infection can result in CIN among subjects that are immunocompromised and infected with HIV, and have a history of smoking.
According to the Centers for Disease Control and Prevention (CDC), cervical cancer due to HPV infection is the ninth most common cancer among women in the US, and each year, ~13 million people are infected with HPV infection. According to the HPV Information Center, US, in 2023, ~3.9% of women are likely to be infected with cervical HPV 16 or 18, and 71.2% of cervical cancers are attributed to HPVs 16 or 18. According to the European Cancer Organization, in 2020, HPV infections were the cause of ~2.5% of cancer cases in Europe, and the prevalence of high-risk HPV infection exceeds 15% among the European population. According to the World Health Organization, ~66,000 women were diagnosed with cervical cancer in the WHO European region in 2022. According to a study published in the National Library of Medicine, in 2020, sub-Saharan Africa had the world’s highest cervical cancer rates, which can be largely attributed to the low screening rate in the region. Cervical cancer accounts for 20–25% of all cancers among women in sub-Saharan Africa, and its incidence ranges from 30 to 40 per 100,000 women, more than double of that reported among women worldwide. In South Africa, cervical cancer is the leading cause of cancer mortality among women; it is the second most common type of cancer among women from the age group of 15–44. According to the same source, ~62.8% of invasive cervical cancer cases in South Africa are caused by HPV 16 or 18. In 21 of the 48 sub-Saharan African countries, cervical cancer ranks among the most common causes of death among women, and almost 100% of all cases of cervical cancer are associated with the high prevalence of HPV.
Thus, a rise in the prevalence of HPV infections contributes to the growth of the CIN & HR-HPV treatment market.
Go through further research published by The Insight Partners: (Purchase with 10% Instant Discount):
Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis
HPV Testing & Pap Test Market Forecast to 2028 - COVID-19 Impact and Global Analysis
Chemotherapy-Induced Neutropenia Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/cin-and-hrhpv-treatment-market